At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 47 enrolled
Drug / intervention
Trifarotenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Study to Evaluate Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Trifarotene for Acne Vulgaris. Completed, enrolled 47 participants across 9 sites.
Detailed Summary
Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedApr 16, 2019
Enrollment StartMar 27, 2019
Primary CompletionDec 23, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.2 years ago
Interventions
Trifarotenedrug
Topical Cream